YC and Ginkgo Bioworks announce new partnership for synthetic biology startups

Re:YC and Ginkgo Bioworks announce new partnership for synth... by nextos on Monday September 16, 2019 @05:09PM (#20988606)

So YC Bio doesn't imply a much bigger investment for 20% equity anymore?

Most bio startups will require a significant amount of capital to bootstrap. It's cheaper now, but still an order of magnitude more than for IT.

[ Parent | on HN ]

Re:YC and Ginkgo Bioworks announce new partnership for synth... by nemanja-mit on Monday September 16, 2019 @05:39PM (#20988837)

Surprisingly, bio is pretty similar to software capital-wise, at least initially and the standard YC deal works well. Jared and Jorge wrote good pieces around this recently -

https://blog.ycombinator.com/how-biotech-startup-funding-wil...

https://techcrunch.com/2019/08/09/biotech-researchers-ventur...

Case in point - Asher Bio from the most recent YC batch went from zero to a working molecule & in-vivo data in ~3 months on the standard deal - https://techcrunch.com/2019/08/20/here-are-the-82-startups-t...

[ Parent | on HN ]

Re:YC and Ginkgo Bioworks announce new partnership for synth... by kayhi on Monday September 16, 2019 @06:41PM (#20989280)

I would see this more of a reflection of spend matching the access to capital not that bio is similar to software. The difference between moving atoms and bits is significant.

[ Parent | on HN ]